SAM Advisors LLC Raises Position in Kenvue Inc. (NYSE:KVUE)

SAM Advisors LLC grew its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 8.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 56,676 shares of the company’s stock after purchasing an additional 4,217 shares during the period. Kenvue makes up approximately 0.4% of SAM Advisors LLC’s holdings, making the stock its 22nd largest position. SAM Advisors LLC’s holdings in Kenvue were worth $1,210,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in KVUE. AMF Tjanstepension AB boosted its position in shares of Kenvue by 187.3% in the 3rd quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock worth $2,787,000 after purchasing an additional 78,540 shares in the last quarter. Sequoia Financial Advisors LLC boosted its position in shares of Kenvue by 6.2% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 24,690 shares of the company’s stock worth $571,000 after purchasing an additional 1,449 shares in the last quarter. Signaturefd LLC boosted its position in shares of Kenvue by 394.0% in the 3rd quarter. Signaturefd LLC now owns 4,061 shares of the company’s stock worth $94,000 after purchasing an additional 3,239 shares in the last quarter. Commerzbank Aktiengesellschaft FI bought a new stake in shares of Kenvue in the 3rd quarter worth approximately $292,000. Finally, International Assets Investment Management LLC raised its holdings in Kenvue by 1,529.5% in the 3rd quarter. International Assets Investment Management LLC now owns 106,341 shares of the company’s stock worth $2,460,000 after acquiring an additional 99,815 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Trading Up 4.1 %

NYSE:KVUE opened at $23.31 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm has a market capitalization of $44.68 billion, a price-to-earnings ratio of 43.97, a price-to-earnings-growth ratio of 2.62 and a beta of 1.45. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The business has a fifty day moving average price of $21.29 and a 200-day moving average price of $22.14.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.52%. Kenvue’s dividend payout ratio (DPR) is 154.72%.

Analyst Ratings Changes

KVUE has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Citigroup decreased their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. UBS Group decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Finally, Barclays decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $23.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.